Human papillomavirus vaccination induces neutralising antibodies in oral mucosal fluids
| Autor: | Andrea Haitel, T Senger, Reinhard Kirnbauer, Alessandra Handisurya, Christina Schellenbacher |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
0301 basic medicine Cancer Research Saliva Adolescent Antibodies Viral Immunoglobulin G Young Adult 03 medical and health sciences Papillomavirus Vaccines 0302 clinical medicine Humans Medicine Papillomaviridae human papillomavirus neutralising antibodies oropharyngeal disease HPV vaccination biology business.industry Papillomavirus Infections Mouth Mucosa HPV infection pseudovirion neutralisation assay virus diseases biology.organism_classification medicine.disease Antibodies Neutralizing oral fluids Virology Human papillomavirus vaccination In vitro 030104 developmental biology Oncology 030220 oncology & carcinogenesis Immunology biology.protein Female Antibody Translational Therapeutics business |
| Zdroj: | British Journal of Cancer |
| ISSN: | 1532-1827 0007-0920 |
| DOI: | 10.1038/bjc.2015.462 |
| Popis: | Background: Mucosal human papillomaviruses (HPV) are a major cause of cancers and papillomas of the anogenital and oropharyngeal tract. HPV-vaccination elicits neutralising antibodies in sera and cervicovaginal secretions and protects uninfected individuals from persistent anogenital infection and associated diseases caused by the vaccine-targeted HPV types. Whether immunisation can prevent oropharyngeal infection and diseases and whether neutralising antibodies represent the correlate of protection, is still unclear. Methods: We determined IgG and neutralising antibodies against low-risk HPV6 and high-risk HPV16/18 in sera and oral fluids from healthy females (n=20) before and after quadrivalent HPV-vaccination and compared the results with non-vaccinated controls. Results: HPV-vaccination induced type-specific antibodies in sera and oral fluids of the vaccinees. Importantly, the antibodies in oral fluids were capable of neutralising HPV pseudovirions in vitro, indicating protection from infection. The increased neutralising antibody levels against HPV16/18 in sera and oral fluids post-vaccination correlated significantly within an individual. Conclusions: We provide experimental proof that HPV-vaccination elicits neutralising antibodies to the vaccine-targeted types in oral fluids. Hence, immunisation may confer direct protection against type-specific HPV infection and associated diseases of the oropharyngeal tract. Measurement of antibodies in oral fluids represents a suitable tool to assess vaccine-induced protection within the mucosal milieu of the orophayrynx. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink